Claris Bio Raises $118 Million for Pivotal CSB-001 Development

Company Claris Bio Event Type Financing (Series B) Modality Ocular-surface / corneal repair therapeutic Asset CSB-001 Target Corneal surface regeneration Disease Area Limbal stem-cell deficiency Summary Claris Bio announced a $118 million Series B financing intended to advance CSB-001 through pivotal development for limbal stem-cell…